All these data validated that pharmacological regulation of STAT3 activity could regulate osteoblast differentiation in vitro and modulate bone metabolism in vivo, suggesting that STAT3 may act as a suitable pharmacological target for treatment of AD-HIES-related skeletal defects and other bone disorders by regulating osteogenesis. This evidence concerns the gene STAT3 and bone disorder.